Ann: Investor Presentation, page-383

and yet here we are doing a US FDA approved and global controlled trial in GvHD, which I imagine without needing much imagination really will be worth way north of the $US60m deal struck with Fuji pre clinical after Phase 2.

A trial that is randomly controlled
Has a proper assay
Is in the main GvHD Adult population
Is larger than MSBs only GvHD trial in 11 years.
and NO US office

and I for one thank Fuji for the A$8m for giving it back
Much better than the middle finger you got from every pharma to date, especially Novartis after wasting over a year of resources.

Do continue exposing yourself though Pledge.
You're here to amuse obviously.